Skip to main content

Advertisement

SpringerLink
Log in

Use of targeted therapy for refractory ALK-positive anaplastic large cell lymphoma as a bridging strategy prior to allogeneic transplantation

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Gambacorti-Passerini C, Messa C, Pogliani EM (2011) Crizotinib in anaplastic large-cell lymphoma. N Engl J Med 364:775–776

    Article  PubMed  Google Scholar 

  2. Kwak EL, Bang YJ, Camidge DR, Shaw AT et al (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693–1703

    Article  PubMed  CAS  Google Scholar 

  3. Shaw AT, Yeap BY, Solomon BJ, Riely GJ et al (2011) Effect of Crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 11:1004–1012

    Article  Google Scholar 

  4. Younes A, Bartelett NL, Leonard JP, Kennedy DA et al (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363:1812–1821

    Article  PubMed  CAS  Google Scholar 

  5. Van Besien K (2011) Current status of allogeneic transplantation for aggressive non-Hodgkin lymphoma. Curr Opin Oncol 23:681–691

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The authors would like to thank Pfizer and Seattle Genetics allowing us to use Crizotinib and Brentuximab within the framework of a compassionate use program.

Author information

Authors and Affiliations

  1. Medical Clinic and Policlinic I, University Hospital, Fetscherstrasse 74, 01307, Dresden, Germany

    R. Ordemann, J. Stöhlmacher, F. Kroschinsky, J. M. Middeke, U. Platzbecker, M. Bornhäuser & G. Ehninger

  2. Department of Radiation Oncology, University Hospital, Fetscherstrasse 74, 01307, Dresden, Germany

    B. Beuthien-Baumann & I. Platzek

  3. PET Center, Institute of Radiopharmacy, Helmholtz-Zentrum Dresden-Rossendorf, 01314, Dresden, Germany

    J. van den Hoff

  4. Department of Pathology, University Hospital, Fetscherstrasse 74, 01307, Dresden, Germany

    C. Zietz

Authors
  1. R. Ordemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Stöhlmacher
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. Beuthien-Baumann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. I. Platzek
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. van den Hoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. F. Kroschinsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J. M. Middeke
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. U. Platzbecker
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. C. Zietz
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M. Bornhäuser
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. G. Ehninger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Ordemann.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ordemann, R., Stöhlmacher, J., Beuthien-Baumann, B. et al. Use of targeted therapy for refractory ALK-positive anaplastic large cell lymphoma as a bridging strategy prior to allogeneic transplantation. Ann Hematol 92, 125–127 (2013). https://doi.org/10.1007/s00277-012-1524-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-012-1524-0

Keywords

Search

Navigation